Invention Application
- Patent Title: ANTISENSE OLIGONUCLEOTIDE TARGETING ARL4C MOLECULE, AND NUCLEIC ACID DRUG USING ANTISENSE OLIGONUCLEOTIDE
-
Application No.: US17250806Application Date: 2019-09-04
-
Publication No.: US20210317459A1Publication Date: 2021-10-14
- Inventor: Akira KIKUCHI , Shinji MATSUMOTO , Satoshi OBIKA , Yuya KASAHARA , Takumi FUKUMOTO
- Applicant: OSAKA UNIVERSITY , NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION , NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
- Applicant Address: JP Suita-shi, Osaka; JP Ibaraki-shi, Osaka; JP Kobe-shi, Hyogo
- Assignee: OSAKA UNIVERSITY,NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION,NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
- Current Assignee: OSAKA UNIVERSITY,NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION,NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
- Current Assignee Address: JP Suita-shi, Osaka; JP Ibaraki-shi, Osaka; JP Kobe-shi, Hyogo
- Priority: JP2018-165544 20180905
- International Application: PCT/JP2019/034746 WO 20190904
- Main IPC: C12N15/113
- IPC: C12N15/113 ; A61P35/04
Abstract:
The purpose of the present invention is to provide an antisense oligonucleotide that targets an ARL4C molecule and exerts an antitumor effect in vivo, and a nucleic acid drug using the antisense oligonucleotide. An antisense oligonucleotide that has a base sequence consisting of at least 10 consecutive bases contained in the base sequence represented by SEQ ID NO: 1. This antisense oligonucleotide targets an ARL4C molecule and thus can inhibit the expression of ARL4C in a tumor cell in vitro and suppress the migration and proliferation thereof. When systemically administered, moreover, the antisense oligonucleotide can exert an excellent antitumor effect in vivo too.
Public/Granted literature
- US12071624B2 Antisense oligonucleotide targeting ARL4C molecule, and nucleic acid drug using antisense oligonucleotide Public/Granted day:2024-08-27
Information query
IPC分类:
